Logo

Michael French, Victor Ambros, David Baulcombe, Gary Ruvkun

Sep 18, 2008
Premium
MDRNA CEO Michael French has been appointed to the company’s board, and has also been named as president.
 
French joined MDRNA, which previously was known as Nastech Pharmaceutical (see RNAi News, 6/12/2008), in June. He previously served as senior vice president of corporate development at Sirna Therapeutics.
 
 
Victor Ambros, David Baulcombe, and Gary Ruvkun were awarded this year’s Albert Lasker Medical Research Awards for their pioneering efforts in discovering microRNAs.
 
Ambros recently became a professor at the University of Massachusetts Medical School. Baulcombe is a professor at the University of Cambridge, and Ruvkunis a professor at Harvard Medical School.

Filed under

Gene Editing, Gene Silencing, & CRISPR
RNAi
Breaking News
The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.